KS

Kevin Slawin

Chairman and CEO of PrintBio

Miami Beach, Florida

Overview 

Kevin Slawin is the Founder and CEO of Ponce Therapeutics, Inc. and Deliver Therapeutics, Inc. in Houston, TX, pioneering the development of groundbreaking therapeutics to halt or reverse aging through advanced technologies. With a background in lifesciences and a successful track record in the biotechnology industry, he has also served as Chairman and CEO of PrintBio, Inc., demonstrating expertise in clinical strategy and pharmaceuticals. Kevin Slawin's career highlights include founding and leading multiple successful companies, such as Ponce Therapeutics, Inc. and Deliver Therapeutics, Inc., where he is at the forefront of innovative approaches to aging therapeutics. Additionally, his investment in companies like FIZE Medical and AsclepiX Therapeutics showcases his commitment to advancing healthcare through strategic investments.

Work Experience 

  • Chairman, Founder and CEO

    2024 - Current

    “Improving Healthspan and Increasing Lifespan” Senotherapeutix is a longevity holding company using advanced technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. Its wholly owned subsidiary companies are developing products, both senolytic and senomorphic in nature, using our proprietary, state-of-the-art biotechnology platforms to restore the youthful balance of aged or “senescent” and young cells throughout the organs of the body. By targeting senescent cells, we have a unique opportunity to intervene in the aging process in ways that were once thought impossible.

  • Chairman, Founder and CEO

    2024

    "Improving Healthspan and Increasing Lifespan" Eos SENOLYTIX is a longevity company using advanced technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead programs, PTC-2105 and PTC-2107, our proprietary senolytic peptides, restore the youthful balance of aged or “senescent” and young cells throughout the organs of the body. By targeting senescent cells for elimination, we have a unique opportunity to intervene in the aging process in ways that were once thought impossible.

  • Chairman, Founder and CEO

    2024

    "Improving Healthspan and Increasing Lifespan" Phoenix SENOLYTIX is a longevity company using advanced technologies to develop novel gene therapies targeting the fundamental mechanisms of aging. Its lead program, utilizing its proprietary purposeful cell elimination technology, ApoptiCIDe™, targets senescent cells for elimination, restoring the youthful balance of aged or “senescent” and young cells throughout the organs of the body. Our leadership team were the founders of Bellicum Pharmaceuticals, the first CAR-T cell company, in 2004. Inventors of CaspaCIDe™ at Bellicum, the most effective cell therapy safety switch validated in humans, they have now repurposed this technology, previously established as both safe and effective senolytic therapy in the p16Ink4a-ATTAC mouse model of genomic ablation of senescent cells, now as ApoptiCIDe™ to target senescent cells for non-inflammatory, apoptotic elimination, among other uses, in patients. By targeting senescent cells for elimination, we have a unique opportunity to intervene in the aging process in ways that were once thought impossible

  • Chairman, Founder and CEO

    2023

    “Powered by Advanced and Clinically Tested Bioprinting Technologies” PrintBio is deploying technologies utilized to manufacture and implant the first 3D-bioprinted living tissues in patients PrintBio is the only clinical- and commercial-stage regenerative medicine company solving medical challenges with custom-engineered 3D-bioprinted living implants. Leveraging first-in-human clinical experience, PrintBio is developing an array of products, beginning with 3DMatrix™, an FDA 510(k)-cleared 3D-printed monofilament bioresorbable surgical mesh, and next generation product 3DMatrix Dynaflex™ (FDA 510(k) clearance pending) that incorporates PrintBio’s proprietary Uniflex™ unidirectional flexible mesh technology, both utilizing proprietary technologies clinically tested in patients.

  • Founder, CEO and Chairman

    2021

    Applying high throughput DNA encoded library (DEL) drug screening technologies in novel ways to deliver therapeutics that address the most difficult problems in clinical medicine

DELIVER Therapeutics provides modern research tools and approaches are rapidly implicating new types of disease.

  • Founder and Managing Partner

    2018

    Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

Rapha Capital Management is an investment company that invests in early stage biotechnology companies.

  • Chairman of the Board

    2022

    Conquering the Last Frontier in Patient Monitoring. FIZE® Medical offers the first platform technology to remotely monitor and manage patients with an indwelling Foley catheter, providing unprecedented safety to both patients and their caregivers.

  • Board Member

    2020 - 2022

  • Founder and Chairman

    2021

    Physicians, founders, executives and investors working to expand the entrepreneurial healthcare ecosystem in Miami

Miami Medicos is a member organization supporting the business needs of Biopharma, medical devices and services companies.

  • Chairman of the Board

    2021

    Building a Best-in-class Urologic Oncology Company. Developing technologies to better visualize and treat urologic cancers through minimally invasive procedures in the physicians’ office

Imagin Medical is a surgical imaging company.

Raised $11,000,000.00 from Rapha Capital Management and Rapha Capital Management.

  • Founding Board Member

    2021

    Enabling promising early-stage life science companies to develop the next generation of innovative therapies to improve the lives of patients. We want to do this by offering them Contract Research Organization (CRO) Services, newly renovated wet-lab space, process and analytical development support, short-term financing, and third-party due diligence validation, among other services.

K2bio is a contract research organization that assists early-stage life science companies in advancing innovative therapies.

Raised $615,522.00.

Articles About Kevin

Relevant Websites